Crysvita (burosumab-twza) / Ultragenyx, Kyowa Kirin - LARVOL DELTA

Can Burosumab Offer Functional and Cardiovascular Benefits Over Conventional Therapy in Adults With XLH? (ASBMR 2025) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular

Reduction in Serum Alkaline phosphatase Is Correlated with Improvement in Rickets Severity Score in Children with XLH Treated with Burosumab: SUNFLOWER Study Analysis (ASBMR 2025) - P | No abstract available

Clinical

Long-Term Burosumab Treatment in Tumor-Induced Osteomalacia Due to an Undetectable Tumor (ASBMR 2025) - No abstract available

Late-breaking abstract • Oncology

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia (ASBMR 2025) - No abstract available

Clinical • P2 data • Renal Disease • FGF23

Burosumab Use in FGF-23 Mediated Hypophosphatemia in McCune Albright Syndrome (ASBMR 2025) - No abstract available

Genetic Disorders • Renal Disease • FGF23

Pain Management Among Patients With X-linked Hypophosphatemia (XLH) Prior to Treatment With Burosumab: A Retrospective Analysis (ASBMR 2025) - No abstract available

Retrospective data • Pain • Renal Disease

Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults With X-Linked Hypophosphatemia (XLH) in a Real-World Setting: A 3-Year Follow-up of the XLH Disease Monitoring Program (ASBMR 2025) - P | No abstract available

Clinical • Real-world • Real-world evidence • Renal Disease

Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children and Adolescents with X-linked Hypophosphataemia: Second Interim Analysis (ASBMR 2025) - P | No abstract available

Clinical • Renal Disease

Burosumab Improves Short Stature in Children with X-linked Hypophosphatemia with Low Rickets Severity: SUNFLOWER Analysis (ASBMR 2025) - P | No abstract available

Clinical • Renal Disease

Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Adults with X-linked Hypophosphataemia: First Interim Analysis (ASBMR 2025) - P | No abstract available

Clinical • Renal Disease

Biochemical and Patient-reported Outcomes in Tumor-induced Osteomalacia patients treated and not treated with burosumab (ASBMR 2025) - P | No abstract available

Clinical • Patient reported outcomes • Oncology

Pain, stiffness and fatigue experienced by adolescents living with X-linked hypophosphataemia (XLH): a mixed-methods comparison of those who continued vs discontinued burosumab treatment following end of skeletal growth (EoSG) (ASBMR 2025) - No abstract available

Fatigue • Pain • Renal Disease

Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children and Adolescents with X-linked Hypophosphataemia: Second Interim Analysis (ASBMR 2025) - P | No abstract available

Clinical • Renal Disease

Reduction in Serum Alkaline phosphatase Is Correlated with Improvement in Rickets Severity Score in Children with XLH Treated with Burosumab: SUNFLOWER Study Analysis (ASBMR 2025) - P | No abstract available

Clinical

Burosumab Improves Short Stature in Children with X-linked Hypophosphatemia with Low Rickets Severity: SUNFLOWER Analysis (ASBMR 2025) - P | No abstract available

Clinical • Renal Disease

Acquired Osteomalacia Associated with Autoantibodies against PHEX (ASBMR 2025) - "Utilizing luciferase immunoprecipitation systems: LIPS and flowcytometry: FCM, 5 patients were identified to possess anti-PHEX antibodies and presented relatively mild phenotypes of osteomalacia which rather resembles the severity of X-linked hypophosphatemic rickets rather than the one of tumor-induced osteomalacia, and we named this condition "autoimmune osteomalacia: AIO." 4 out of 5 patients have been treated with burosumab and osteomalacia achieved remission. Previously reported case with suspected AIO with systemic lupus erythematosus suggested the efficacy of glucocorticoid on this condition."

Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Adults with X-linked Hypophosphataemia: First Interim Analysis (ASBMR 2025) - P | No abstract available

Clinical • Renal Disease

Pain, stiffness and fatigue experienced by adolescents living with X-linked hypophosphataemia (XLH): a mixed-methods comparison of those who continued vs discontinued burosumab treatment following end of skeletal growth (EoSG) (ASBMR 2025) - No abstract available

Fatigue • Pain • Renal Disease

Comprehensive Genetic and Pathologic Insights Into Tumor-Induced Osteomalacia: Advances in Diagnostics, Multidisciplinary Care, and Orthopedic Management Strategies (CAP 2025) - "Complete tumor resection normalized phosphate metabolism in 90% of patients, with adjunctive burosumab therapy improving refractory cases by 70%... Multidisciplinary care integrating advanced imaging, genetic profiling, and surgical innovations optimizes TIO management. Early diagnosis and tailored therapies significantly reduce morbidity. Future directions include developing cost-effective imaging alternatives and refining precision medicine strategies."

Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Orthopedics • Pain • Rare Diseases • FGF23

Diagnosis and Management of Hypophosphatemic Disorders. (PubMed, Endocr Pract) - "In the past few decades, significant progress has been made in identifying the genetic causes of and novel therapies for hypophosphatemic disorders. In this review, the regulation of phosphate homeostasis, clinical presentation, work-up, disorders, and treatment of hypophosphatemia will be discussed."

Journal • Review • Renal Disease • FGF23

Tumor Induced Osteomalacia Caused by Metastatic Thyroid Cancer (ENDO 2025) - "Cabozantinib, a tyrosine kinase inhibitor, and palliative radiation therapy were initiated along with zoledronate... TIO is a rare paraneoplastic disorder often associated with phosphaturic mesenchymal tumors. The patient's clinical presentation of severe FGF23 mediated hypophosphatemia and diffuse skeletal fragility was initially misattributed to metastatic poorly differentiated thyroid cancer. Despite extensive evaluation, no secondary mesenchymal tumor was identified on imaging."

Metastases • Endocrine Cancer • Endocrine Disorders • Fatigue • Musculoskeletal Diseases • Oncology • Pain • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • FGF23

Burosumab: What can it do in children and adult patients with X-linked hypophosphatemia? (PubMed, J Bone Miner Res) - No abstract available

Journal • Renal Disease

Non-interventional Post-authorisation Safety Study Of Burosumab In The Treatment Of Adults With X-linked Hypophosphataemia: First Interim Analysis (ENDO 2025) - P | "No deaths, events of hyperphosphataemia or SAE considered related to burosumab were reported. The higher AE rate in BUR+ vs Pi/VitD+ is likely attributed to differences in reporting."

Clinical • Late-breaking abstract • Back Pain • Chronic Kidney Disease • Endocrine Disorders • Gastroenterology • Hepatology • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Oncology • Pain • Renal Calculi • Renal Disease • FGF23

Sustained Improvements in Patient-Reported Outcomes Across Age Groups in Burosumab-Treated X-linked Hypophosphatemia (XLH): Results From the XLH Disease Monitoring Program (ENDO 2025) - P | "Adults with XLH also showed significant improvements at DMP Y1 and 3 in all WOMAC domains. Despite small sample sizes, this analysis provides real-world data on the positive impact of burosumab treatment on PROs."

Clinical • Patient reported outcomes • Fatigue • Immunology • Osteoarthritis • Pain • Renal Disease • Rheumatology • FGF23

Real-World Outcomes in Late Adolescence Among Individuals With X-linked Hypophosphatemia (XLH): Results From the XLH Disease Monitoring Program (ENDO 2025) - P | "ConclusionBiochemical parameters and patient-reported outcomes were generally stable for older adolescents treated with burosumab, suggesting that consistent disease management, as anticipated in the DMP, was in place at a time when many persons may otherwise be lost to follow-up. As the DMP evolves, further analyses will be performed to incorporate additional pts and longer follow-up times to enhance the understanding of outcomes during late adolescence."

Clinical • Real-world • Real-world evidence • Fatigue • Immunology • Osteoarthritis • Pain • Renal Disease • Rheumatology